Cargando…
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
ESSENTIALS: Treatment complications in hemophilia A: inhibitors development. Type of FVIII products: the latest updates on plasma‐derived or recombinant FVIII immunogenicity. SIPPET study, the first randomized study contrasting plasma‐derived FVIII and recombinant FVIII products. The impact of other...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055565/ https://www.ncbi.nlm.nih.gov/pubmed/30046724 http://dx.doi.org/10.1002/rth2.12094 |